RIP3 RIP3 Anticancer supplement composition comprising RIP3 activator Method for screening anticancer supplement agents inducing RIP3 expression for enhancing sensitivity to anticancer agents and method for monitoring sensitivity to anticancer agents

摘要

The present invention relates to an anticancer adjuvant pharmaceutical composition containing a receptor-interacting protein kinase-3 (RIP3) protein expression promoter or activator as an active ingredient. Further, the present invention provides a method for enhancing cancer cell death by administering, to cancer cells, a RIP3 protein expression promoter or activator and an anticancer drug in combination. Furthermore, the present invention relates to: a method for screening for an anticancer adjuvant which enhances the sensitivity of an anticancer drug by promoting RIP3 expression; and a method for monitoring the sensitivity of an anticancer drug through whether or not RIP3 is expressed. Therefore, it is expected that pretreating a demethylation agent so as to induce RIP3 expression and then using a conventional chemotherapeutic agent in a patient lacking RIP3 expression could be an effective treatment strategy. In addition, it is expected that monitoring the sensitivity of an anticancer drug and screening for an anticancer adjuvant enhancing the sensitivity of an anticancer drug in cancer treatment could be an effective strategy.